ABSTRACT. Apx toxins have been identified as important virulence factors of Actinobacillus pleuropneumoniae, the etiologic agent of porcine pleuropneumonia. In some A. pleuropneumoniae serotypes, Apx toxins are secreted by the cell membrane proteins encoded by apxI-IIB and apxIIID genes. In an effort to develop a live vaccine strain against A. pleuropneumoniae, we inactivated the apxIIIB and apxIIID genes in A. pleuropneumoniae 1536, a serotype 2 strain, resulting in the apxIIIB/apxIIID mutant strain (1536BD). Immunization of pigs with live 1536BD A. pleuropneumoniae conferred protection against homologous challenge with wild-type A. pleuropneumoniae 1536. Thus, impaired Apx toxin secretion may decrease the virulence of A. pleuropneumoniae and may be an effective strategy for the development of a live-attenuated A. pleuropneumoniae vaccine.
Actinobacillus pleuropneumoniae is the etiological agent of porcine pleuropneumonia, a contagious respiratory disease of pigs. The disease is characterized by hemorrhagic necrotizing pneumonia and fibrinous pleuritis. A. pleuropneumoniae infection of pigs results in major economic losses for the swine production industry [7] . To date, 15 serotypes of A. pleuropneumoniae have been identified worldwide [3] . Most of those serotypes secrete one or more A. pleuropneumoniae toxin (Apx), identified as ApxI, ApxII, ApxIII, and ApxIV [4, 7, 20] . Apx toxins are major virulence factors of A. pleuropneumoniae and are strongly immunogenic [11] . Thus, the degree of virulence of each A. pleuropneumoniae serotype is likely associated with the secretion of Apx toxins.
The production and secretion of active Apx toxins require the functions of at least four genes, apxC, apxA, apxB, and apxD, which are encoded in a single operon. The apxA gene encodes for the toxin protein itself, and the apxC gene encodes a protein that activates the Apx by post-translational acylation [7, 13] . The apxB and apxD genes encode bacterial inner membrane proteins [14] that are required for secretion of activated Apx [13, 21] . The apx operon structure, which couples the Apx toxin genes with genes that encode the toxin secretion system, suggests that Apx must be efficiently secreted otherwise the highly cytotoxic properties of Apx will be hazardous to the bacteria itself [15] . Thus, mutation of the Apx secretion system represents a potential means of attenuating A. pleuropneumoniae.
It has been shown that pigs surviving natural A. pleuropneumoniae infections are protected from reinfection by any of the other A. pleuropneumoniae serotypes. This suggests that the use of a live-attenuated A. pleuropneumoniae vaccine may be a promising approach to protect against porcine pleuropneumonia [12] . Several mutants of A. pleuropneumoniae have been generated by the inactivation of specific virulence factors and evaluated for their potential as candidate vaccines. Some strains with mutations in metabolic genes such as ribGBAH [8] , aroA [9] , aroQ [10] , ureC, and exbB [2] have been constructed. Additionally, various Apxmutant strains have also been generated and tested as liveattenuated vaccine candidates. For example, an apxIA mutant of A. pleuropneumoniae serotype 10 provided partial protection of vaccinated pigs upon challenge with serotypes 1 and 2 [22] . Pigs vaccinated with an apxIIC mutant of serotype 7, which produces only inactive ApxII toxins, were protected against a challenge with A. pleuropneumoniae serotype 1 [19] . In addition, Lin et al. [16] constructed a live-attenuated serotype 1 strain by deleting both the apxIC and apxIIC genes. This mutant strain expressed and secreted inactive ApxI and ApxII toxins and induced an immune response in pigs.
Although strains with mutations in the apxA and apxC genes have been frequently developed as attenuated vaccine candidates, the generation of candidate vaccines strains with mutations in the apxB and apxD genes has not been reported. To determine if deletion of the Apx secretion system attenuates A. pleuropneumoniae, we have constructed a mutant strain of A. pleuropneumoniae serotype 2 (strain 1536), which retains the apxIBD, apxIICA, and apxIIICABD genes, but has inactivating mutations in the apxIIIB and apxIIID genes (1536BD). 1536BD was tested as a vaccine candidate to examine its protective efficacy against wild-type A. pleuropneumoniae infection in pigs.
MATERIALS AND METHODS
Chemicals: All chemicals were of reagent grade or higher and purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise specified.
Bacterial strains, plasmids and growth conditions: A. pleuropneumoniae strains were grown in pleuropneumonialike organism (PPLO) media (BD Biosciences, Sparks, MD) supplemented with nicotinamide dinucleotide (10 g/ml), L-cysteinehydrochloride (260 g/ml), L-glutamine (100 g/ ml), dextrose (1 mg/ml), L-cystine-dihydrochloride (10 g/ ml), and Tween 80 (0.1%) at 37C with continuous shaking [1] . Escherichia coli were grown in Luria-Bertani media for routine cultivation. Antibiotic concentrations for maintaining plasmids in E. coli were 100 g/ml for ampicillin, and 50 g/ml for kanamycin.
Serotyping:
The serotype of A. pleuropneumoniae 1536 strain (ATCC 27089, serotype 2) was confirmed by polymerase chain reaction (PCR) genotyping and slide agglutination analyses. For genotyping, genomic DNA was extracted from the 1536 strain using a commercially available kit (Intron, Kyunggido, Korea) and used for PCR amplification with three separate primer pairs specific to the apxICA, apxIICA, and apxIIICA loci, which are X1CA-F and X1CA-R, X2CA-F and X2CA-R, and X3CA-F and X3CA-R, respectively (Table 1) .
For slide agglutination, the 1536 strain was grown on PPLO agar plates overnight at 37C. The growth was harvested gently in phosphate buffered saline (pH 7.2) and 1 ml of the suspension was boiled for 10 min. Equal volumes (50 l) of the bacterial suspension and each genotyping antiserum were mixed on a clean glass slide and the glass slide was rotated by hand for 2 min. The reaction was regarded as positive if agglutination occurred within 2 min [6, 18] . Five rabbit antisera against serotypes 1, 2, 5a, 5b and 8 were kindly provided by Dr. K. R. Mittal (Universite de Montreal, Quebec, Canada).
Recombinant vector: A plasmid vector pBKS-APP-Kan r was designed to contain a fragment of contiguously-located apxIIIB and apxIIID genes (apxIIIBD, GenBank accession number L12145) that were inactivated by the introduction of a Kanr gene. For the plasmid preparation, a 3.2 kb-long fragment of apxIIIBD was amplified from A. pleuropneumoniae 1536 genomic DNA by PCR using primers X3BD-F1 and X3BD-R1. The PCR product was cloned into pGEM T Easy (Promega, Madison, WI) to produce pGEM-App. pGEM-App was digested with Not I and the 3.2 kb insert was ligated into a Not I-linearized pBluescript II KS(+) (Stratagene, La Jolla, CA) to obtain pBKS-App. pBKS-App was digested with Bsm I and Nru I to delete a 770-bp fragment of apxIIIBD. A 1.4-kb fragment encoding Kan r was amplified from pECFP-C1 (BD Biosciences) using primers ECFP-F1 and ECFP-R1. The PCR product was then digested with Bsm I and inserted into the Bsm I and Nru I vector fragment derived from pBKS-App to form pBKS-APP-Kan r .
Transformation of A. pleuropneumoniae 1536 and mutant selection:
Transformation was performed by using a MicroPulser electroporator (Bio-Rad, Hercules, CA), as previously described [1] . In brief, 250 ml of supplemented PPLO medium was inoculated with 25 ml of an overnight culture of the 1536 strain, followed by incubation with shaking to an optical density at 600 nm of 0.3. The culture was chilled on ice for 15 min, and the bacteria were harvested by centrifugation at 4,000  g at 4C. The bacteria were washed three times in 150 ml of ice-cold GYTT medium (10% glycerol, 0.125% Bacto yeast (BD Biosciences), 0.25% Bacto tryptone (BD Biosciences), 0.02% Tween 80). Finally, the cells were resuspended to a final volume of 2.5 ml in GYTT medium. Then, a total of 2 ng of pBKS-APPKan r linearized by Sal I was electroporated (0.2 cm-diameter cuvette, 2.5 kV) into a 0.1 ml aliquot of electro-competent 1536 strain cells. After electroporation, the bacteria were immediately mixed with 1 ml of pre-warmed, supplemented PPLO medium, followed by incubation with shaking for 4 hr at 37C. Transformants were then plated on PPLO agar with 85 g/ml kanamycin and an apxIIIBD mutant (1536BD) was selected and the correct mutation was verified by PCR using three primer pairs ( Table 1 ). The X3BD-F2 and X3BD-R2 primer pair was designed to produce products of 3720 and 4365 bps from the wild-type 1536 and 1536BD genomes, respectively. Two other primer pairs, X3BD-F2 and ECFP-R2 and ECFP-F2 and X3BD-R2, were designed to produce products of 2129 and 1496 bps only from the 1536BD genome, but would not generate a PCR product from a wild-type genome.
Virulence: Ten-week-old female ICR mice (Orient, Seoul, Korea) were maintained with water and food ad libitum in the laboratory animal facilities at the College of Veterinary Medicine, Seoul National University. Wild-type 1536 and 1536BD strains were grown overnight with vigorous shaking at 37C in supplemented PPLO broth. The culture was diluted 1:20 and then incubated again until an OD 600 of 0.8 was reached. At this point, the viable count of A. pleuropneumoniae cells was about 1.0  10 9 CFU/ml. Various dilutions of the cultures were prepared in PPLO broth. Mice were injected intraperitoneally with PPLO containing various doses of bacteria, or PPLO culture media only as a negative control. The number of surviving mice was determined at 72 hr post injection. The dose-response relationship (LD 50 ) was calculated with SPSS probit analysis program (SPSS Inc., Chicago, IL, release 12.0). The Institute of Laboratory Animal Resources of Seoul National University approved all procedures dealing with handling of the animals described in this study.
Protective efficacy of A. pleuropneumoniae 1536BD immunization of mice: The vaccine was prepared by inoculating 10 ml of PPLO broth with a single colony of the A. pleuropneumoniae 1536BD and incubating with shaking at 37C until an OD 600 of 0. Protective efficacy of A. pleuropneumoniae 1536BD immunization of pigs: The vaccine was prepared by inocu-lating 10 ml of PPLO broth with a single colony of the A. pleuropneumoniae 1536BD and incubating with shaking at 37C until an OD 600 of 0.8 was reached. On day zero, 15 three-week-old pigs were randomly divided into three experimental groups and treated intranasally with 2  10 8 CFU of 1536BD or 2 ml of culture media as a negative control. The immunization was repeated on day 14. On day 28 post vaccination, the pigs were challenged intranasally with 1  10 7 CFU of wild-type 1536 or 2 ml of culture media. Animal survival was evaluated for one week postchallenge, and the surviving pigs were then euthanized and lung tissue was removed. The number of lung lesions in each sample was scored and recorded based upon Cho and Chae [5] . Histopathological changes were examined in hematoxylin-eosin stained sections of the lung tissues. The Institute of Laboratory Animal Resources of Seoul National University approved all procedures dealing with handling of the animals described in this study.
RESULTS
Serotyping of A. pleuropneumoniae 1536: Serotype 2 strains are known to have the apxIBD, apxIICA, and apxIII-CABD genes [14] . The genotype of A. pleuropneumoniae 1536 was confirmed by PCR using primer pairs specific to the apxICA, apxIICA, and apxIIICA loci (Fig. 1A) . As expected, the primers specific to apxIICA and apxIIICA loci amplified the expected PCR products of 522 and 720 bps, respectively. No product was produced with a primer pair specific to apxICA locus, which is unrelated to serotype 2 strains. In slide agglutination tests (Fig. 1B) , suspension of the 1536 strain gave a strong positive reaction with antiserum specific to serotype 2, and no cross-reactions were observed between the suspension and anti-sera specific to serotypes 1, 5a, 5b, and 8. These results confirmed that A. pleuropneumoniae 1536 is a serotype 2 strain.
Construction of a apxIIIB/apxIIID mutant strain: Sitespecific mutagenesis of the apxIIIB and apxIIID genes was accomplished by the generation of the recombinant plasmid pBKS-APP-Kan r , as described in the Materials and Methods. The correct mutation was confirmed by PCR screening of clones with three primer pairs, X3BD-F2 and X3BD-R2; X3BD-F2 and ECFP-R2; and ECF-F2 and X3BD-R2 ( Table  1) . As shown in Fig. 2 , PCR products of the expected lengths were amplified with these primer pairs from the genome of the mutant strain, 1536BD. The correct generation of the desired mutation was further confirmed by nucleotide sequencing of the PCR products (data not shown). The 1536BD mutation was stable in vitro over 25 successive passages on PPLO agar plates (data not shown).
Virulence of A. pleuropneumoniae 1536BD: Relative virulence of the wild-type 1536 and 1536BD strains was examined to determine the effect of the mutation in apxII-IBD genes on A. pleuropneumoniae virulence ( Table 2 ). The LD 50 of 1536BD in mice was 6.9  10 
immunization of mice:
To evaluate the ability of the mutant 1536BD strain to protect mice against lethal challenge, mice were immunized with 1536BD twice and challenged with a lethal dose of wild-type A. pleuropneumoniae 1536 ( Table 3) . Eight of the nine mice immunized with 1536BD survived for more than 72 hr after lethal challenge (89% protection), while all eight of the unimmunized mice died by 72 hr after challenge. These data suggest that 1536BD induces a protective immune response against homologous strains of A. pleuropneumoniae. Protective efficacy of A. pleuropneumoniae 1536BD immunization of pigs: Since A. pleuropneumoniae infection of pigs can cause substantial mortality of pig herds, we next evaluated the protective efficacy of the 1536BD mutant strain as a vaccine candidate in pigs (Table 4) . Pigs were vaccinated twice intranasally with 1536BD or media as a negative control, and then challenged with wild-type A. pleuropneumoniae. Immunization of pigs with the 1536BD mutant did not cause histological changes in the lungs tissue (Fig. 3A) . Upon challenge, all 5 unimmunized pigs had lung lesions typical of porcine pleuropneumonia, such as severe diffuse suppurative bronchitis and neutrophil infiltration into alveolar space (Fig. 3B) . These pathological changes were not observed in the lung tissue of pigs immunized with the 1536BD mutant (Fig. 3C) . No animals died in any of the groups during the experimental period.
DISCUSSION
The inactivation of the apxIIIBD genes in the 1536BD mutant (Fig. 2) may inhibit the efficient secretion of Apx toxins, such as ApxIII. ApxIII is strongly cytotoxic for alveolar macrophages and neutrophils [17] . This attenuated phenotype was seen in pigs, because intranasal treatment of pigs with 2  10 Fig. 3) . Thus, the mechanism of attenuation of 1536BD is likely due to the inefficient secretion of the cytotoxic Apx toxins from the bacteria. However, it is also possible that 1536BD attenuation is due to the decreased viability of the bacteria itself due to the accumulation of the highly cytotoxic Apx within the cell. While the pathogenicity of 1536BD was dramatically lower than the parental 1536 strain in pigs, in mice there was only a small, but reproducible, increase in the LD 50 for the 1536BD strain (Table 2) . Such a minor difference in the LD 50 may not be biologically relevant; however, it is interesting that the lowered pathogenicity ( Table 2 ) was consistently observed in each experimental replicate (data not shown). The substantial difference in the degree of attenuation of the 1536BD strain between pigs and mice is striking. The inhibited release of Apx toxins may affect the pathogenicity of A. pleuropneumoniae only minimally in mice, but may reduce pathogenicity in pigs to a greater extent. However, there are a limited number studies on the pathogenicity of A. pleuropneumoniae in mice, so we can only speculated about these results. Another possible explanation for the different level of attenuation for the 1536BD strain between mice and pigs is the route of delivery. The intraperitoneal route is commonly used in studies for the attenuation of A. pleuropneumoniae in mice [16, 19] . In our studies, mice were exposed to A. pleuropneumoniae intraperitoneally, but the pigs were inoculated intranasally. The different route of delivery between the two animal models may affect the lethality of 1536BD and lead to differences in the observed degree of attenuation.
Since pigs that survive natural A. pleuropneumoniae infections are protected against porcine pleuropneumonia, many mutant strains have been developed for use as potential live-attenuated attenuated vaccines. Some of these candidate vaccines are based upon the inactivation of the apxC or the apxA gene [16, 19, 22] , but those mutants have some potential drawbacks. apxA-deficient mutants do not produce any of the Apx toxins, which are important immunogens for the induction of the protective immune response [12] . Mutants lacking an active apxC gene are designed to produce an inactive form of Apx, but inactive Apx may induce a different, less protective immune response than the activated Apx toxins. Thus, apxA-and apxC-deficient mutant strains lack complete forms of Apx toxins, which are highly immunogenic and crucial aspects of the immune response to A. pleuropneumoniae. A central motive of this study was to avoid this drawback by development of a mutant strain that produces a complete form of Apx toxin but releases the toxin only minimally. We hypothesized that pigs treated with the 1536BD mutant strain may be exposed to Apx levels that are sufficient to induce a protective immune response, but not enough to cause pathologic consequences. This is the first study to examine the attenuating effects of ApxB-and ApxD-deletion on A. pleurop- 
neumoniae.
In summary, immunization with a live A. pleuropneumoniae serotype 2 strain, which has been attenuated by mutation of the apxIIIBD genes, protected pigs from challenge by wild-type A. pleuropneumoniae. These results suggest that inactivation of the apxBD genes can be utilized for the development of live-attenuated vaccines against A. pleuropneumoniae. Further studies are required to determine if this class of mutant A. pleuropneumoniae will induce a crossprotective immune response that will protect against a heterologous A. pleuropneumoniae challenge.
